150 related articles for article (PubMed ID: 37902955)
21. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
22. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2.
Lovvorn HN; Renfro LA; Benedetti DJ; Kotagal M; Phelps HM; Ehrlich PF; Lo AC; Sandberg JK; Treece AL; Gow KW; Glick RD; Davidoff AM; Cost NG; Dix DB; Fernandez CV; Dome JS; Geller JI; Mullen EA
J Am Coll Surg; 2024 Apr; 238(4):733-749. PubMed ID: 38251681
[TBL] [Abstract][Full Text] [Related]
23. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
24. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children.
Loke BN; Wong MK; Tawng KD; Kuick CH; Jain S; Lian D; Wagner E; Zou Y; Ganesan V; Sim SW; Lee YT; Chin F; Chan MY; Tan AM; Teh BT; Soh SY; Chang KTE; Loh AHP
Int J Cancer; 2019 Mar; 144(6):1234-1242. PubMed ID: 30362502
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.
Ehrlich PF; Anderson JR; Ritchey ML; Dome JS; Green DM; Grundy PE; Perlman EJ; Kalapurakal JA; Breslow NE; Shamberger RC
J Clin Oncol; 2013 Mar; 31(9):1196-201. PubMed ID: 23382471
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor.
Green DM
J Clin Oncol; 2020 Mar; 38(7):772-773. PubMed ID: 31951492
[No Abstract] [Full Text] [Related]
27. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.
Grundy RG; Pritchard J; Scambler P; Cowell JK
Br J Cancer; 1998 Nov; 78(9):1181-7. PubMed ID: 9820177
[TBL] [Abstract][Full Text] [Related]
28. Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Fernandez CV; Anderson J; Breslow NE; Dome JS; Grundy PE; Perlman EJ; Green DM;
Pediatr Blood Cancer; 2009 Feb; 52(2):254-8. PubMed ID: 18989885
[TBL] [Abstract][Full Text] [Related]
29. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Dome JS; Mullen EA; Dix DB; Gratias EJ; Ehrlich PF; Daw NC; Geller JI; Chintagumpala M; Khanna G; Kalapurakal JA; Renfro LA; Perlman EJ; Grundy PE; Fernandez CV
J Natl Compr Canc Netw; 2021 Aug; 19(8):978-985. PubMed ID: 34416705
[TBL] [Abstract][Full Text] [Related]
30. How many lymph nodes are enough? Assessing the adequacy of lymph node yield for staging in favorable histology wilms tumor.
Saltzman AF; Smith DE; Gao D; Ghosh D; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
J Pediatr Surg; 2019 Nov; 54(11):2331-2335. PubMed ID: 31255328
[TBL] [Abstract][Full Text] [Related]
31. Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2.
Benedetti DJ; Renfro LA; Tfirn I; Daw NC; Kalapurakal JA; Ehrlich PF; Khanna G; Perlman E; Warwick A; Gow KW; Paulino AC; Seibel NL; Grundy P; Fernandez CV; Geller JI; Mullen EA; Dome JS
Cancer; 2024 Jul; 130(13):2361-2371. PubMed ID: 38396300
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of event-free survival in patients with Wilms tumor undergoing preoperative chemotherapy. Analysis of lymph-node yield in a single-center cohort.
Flores P; Cadario M; Strambach J; Sanjuanelo M; Saleme JM; Paz E; Cacciavillano W; Felizzia G; Galluzzo L; Corbetta JP
J Pediatr Urol; 2021 Apr; 17(2):227.e1-227.e5. PubMed ID: 33309612
[TBL] [Abstract][Full Text] [Related]
33. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity on chromosome 16q increases relapse risk in Wilms' tumor: a meta-analysis.
Pan Z; He H; Tang L; Bu Q; Cheng H; Wang A; Lyu J; You H
Oncotarget; 2017 Sep; 8(39):66467-66475. PubMed ID: 29029528
[TBL] [Abstract][Full Text] [Related]
35. New approaches to risk stratification for Wilms tumor.
Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
[TBL] [Abstract][Full Text] [Related]
36. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
[TBL] [Abstract][Full Text] [Related]
37. Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5.
Kieran K; Anderson JR; Dome JS; Ehrlich PF; Ritchey ML; Shamberger RC; Perlman EJ; Green DM; Davidoff AM
J Pediatr Surg; 2012 Apr; 47(4):700-6. PubMed ID: 22498384
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
Madanat-Harjuoja LM; Renfro LA; Klega K; Tornwall B; Thorner AR; Nag A; Dix D; Dome JS; Diller LR; Fernandez CV; Mullen EA; Crompton BD
J Clin Oncol; 2022 Sep; 40(26):3047-3056. PubMed ID: 35580298
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
40. Factors affecting lymph node sampling patterns and the impact on survival of lymph node density in patients with Wilms tumor: a Surveillance, Epidemiology, and End Result (SEER) database review.
Walker JP; Johnson JS; Eguchi MM; Saltzman AF; Cockburn M; Cost NG
J Pediatr Urol; 2020 Feb; 16(1):81-88. PubMed ID: 31791906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
